Global Dermatology Drugs Market to 2023 - Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis
Summary Dermatology is a highly diverse therapy area that deals with diseases of the skin, hair and nails. Over 3,000 types of dermatological conditions are thought to exist, ranging from the autoimmune disorder psoriasis to the very common condition acne vulgaris. The scope of dermatological disorders is diverse in terms of severity and clinical presentation, and if a condition is not sufficiently kept under control, it can significantly impair the patient’s quality of life. For example, patients with severe atopic dermatitis (the most common form of eczema) may experience mobility impairments and debilitating itching, which may interfere with daily activities. Furthermore, most dermatological conditions are visible, and as such can have a profound impact on patient confidence.
There are 850 products in the dermatology pipeline with a disclosed stage of development, but the majority of these drugs are at an early stage of development. Some 42% of the pipeline is in the Preclinical stage, while 14% is in the discovery stage. However, 32% of the pipeline is in clinical development, but only 3% are in the Pre-registration stage and less than half are novel.
Four drugs that were approved for psoriasis are Cosentyx, Otezla, Eucrisa and Taltz. The most notable of the four are Cosentyx and Otezla, which were approved in 2015 and 2014, respectively, and are forecast to generate $3.8 billion and $2.7 billion from the therapy area in 2023, respectively. The two most recently approved psoriasis treatments, Taltz and Eucrisa, are not expected to achieve the same level of commercial success as Cosentyx or Otezla because they are entering a market that is already saturated with entrenched competitors that have reduced the level of unmet need.
Dermatology therapy area is dominated by top 20 pharma companies. In 2016 the most commercially successful companies in the therapy area were Johnson & Johnson, AbbVie, Amgen, Novartis and Pfizer. Across the forecast period these companies will continue to generate high revenue, but the companies will all see their market shares change.
The report “Global Dermatology Drugs Market to 2023 - Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis” provides an introduction to dermatology, including disease epidemiology, symptoms, etiology, pathophysiology, co-morbidities and complications. Disease classification and methods of diagnosis are also provided.
In depth, this report provides the following - - Provides an overview of the dermatology marketed products landscape, including product profiles of key marketed products and revenue projections for each of these drugs. - Analyzes the dermatology pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications in the pipeline: atopic dermatitis, acne vulgaris and psoriasis. - Presents forecast projections to 2022 on a global level, with forecasts provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan. Additionally, revenue forecasts for the major product categories and key players are provided. - Assesses the company landscape in dermatology, with an analysis of the key players, the types of company involved in this therapy area, and whether this therapy area composes a large proportion of each company’s pipeline portfolio and total revenues.
Companies mentioned in this report: Johnson & Johnson, AbbVie, Amgen, Novartis, Pfizer
Scope - Global revenue from the dermatology market is forecast to increase from $19.8 billion in 2016 to $36.6 billion in 2023, at a compound annual growth rate of 9.13%. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period? - What are the leading companies in terms of market share? - Which companies are forecast to experience the largest growth in market share? - Which companies rely heavily on revenue derived from antibacterial drugs? - How will the market respond to recent approvals? - Will generics and biosimilars have a significant impact on the market over the forecast period? - What class of drugs dominate the market? - What molecular targets are most popular in the pipeline? - What are the commercial prospects for the most promising late-stage products?
Reasons to buy - Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action. - Analyze the dermatology pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target. - This review also provides a detailed look at dermatology product clinical trials to provide an insight into the risk associated with attempting to bring pipeline products to market. - Predict growth in market size, with in-depth market forecasting from 2016 to 2023. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value. - Identify commercial opportunities in the dermatology deals landscape by analyzing trends in licensing and co-development deals.
Our reports have been used by over 10K customers, including:
219 pages •
By Asia Market Information & Development Company
• Oct 2019
China’s demand for Monoclonal Antibody has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer...
Integrin Alpha 4 - Pipeline Review, H2 2019 Summary Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) pipeline Target constitutes close to 16 molecules. The latest report Integrin Alpha 4 - Pipeline Review, H2 2019, outlays comprehensive information on the...
Integrin Beta 7 - Pipeline Review, H2 2019 Summary Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Integrin beta-7 is an integrin protein encoded by the ITGB7 gene. It interacts with the cell surface adhesion molecules MADCAM1 which is normally expressed by the vascular endothelium...
Blood Glucose Meters - Medical Devices Pipeline Assessment, 2019 Summary Medical Devices sector report, "Blood Glucose Meters - Medical Devices Pipeline Assessment, 2019", provides an overview of Blood Glucose Meters currently in pipeline stage. The report provides comprehensive information...
Warts - Pipeline Review, H2 2019 Summary The latest Pharmaceutical and Healthcare disease pipeline guide Warts - Pipeline Review, H2 2019, provides an overview of the Warts (Infectious Disease) pipeline landscape. Warts are skin growth that is caused by virus called human papillomavirus (HPV)....
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.